JP2012508172A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508172A5
JP2012508172A5 JP2011534887A JP2011534887A JP2012508172A5 JP 2012508172 A5 JP2012508172 A5 JP 2012508172A5 JP 2011534887 A JP2011534887 A JP 2011534887A JP 2011534887 A JP2011534887 A JP 2011534887A JP 2012508172 A5 JP2012508172 A5 JP 2012508172A5
Authority
JP
Japan
Prior art keywords
factor according
coagulation factor
starch
amino acid
coagulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011534887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508172A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063151 external-priority patent/WO2010062768A1/en
Publication of JP2012508172A publication Critical patent/JP2012508172A/ja
Publication of JP2012508172A5 publication Critical patent/JP2012508172A5/ja
Pending legal-status Critical Current

Links

JP2011534887A 2008-11-03 2009-11-03 血友病の治療方法 Pending JP2012508172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11080908P 2008-11-03 2008-11-03
US61/110,809 2008-11-03
PCT/US2009/063151 WO2010062768A1 (en) 2008-11-03 2009-11-03 Method for the treatment of hemophilia

Publications (2)

Publication Number Publication Date
JP2012508172A JP2012508172A (ja) 2012-04-05
JP2012508172A5 true JP2012508172A5 (enExample) 2012-12-20

Family

ID=42225997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534887A Pending JP2012508172A (ja) 2008-11-03 2009-11-03 血友病の治療方法

Country Status (7)

Country Link
US (1) US20120027743A1 (enExample)
EP (1) EP2352515A4 (enExample)
JP (1) JP2012508172A (enExample)
KR (1) KR20110093775A (enExample)
CN (1) CN102202684A (enExample)
CA (1) CA2740793A1 (enExample)
WO (1) WO2010062768A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
WO2009086400A2 (en) * 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
DK2349314T3 (da) * 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2013160005A1 (en) 2012-04-24 2013-10-31 Novo Nordisk A/S Pharmaceutical composition suitable for treatment of haemophilia
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子viii-xten融合物及其用途
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US8465468B1 (en) * 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Fviii의 부위 지향 변형
WO2006103298A2 (en) * 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Blood coagulation fviii analogues
WO2008081024A1 (en) * 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix

Similar Documents

Publication Publication Date Title
JP2013519636A5 (enExample)
Kadajji et al. Water soluble polymers for pharmaceutical applications
Nita et al. New trends in bio-based aerogels
JP2018040002A5 (enExample)
Chan et al. Pectin as a rheology modifier: Origin, structure, commercial production and rheology
Moscovici Present and future medical applications of microbial exopolysaccharides
Dumitriu et al. Polymeric biomaterials
JP2018535704A5 (enExample)
JP2008516735A5 (enExample)
JP2013519697A5 (enExample)
Hardy et al. β-Cyclodextrin-functionalized chitosan/alginate compact polyelectrolyte complexes (CoPECs) as functional biomaterials with anti-inflammatory properties
JP2016073641A5 (enExample)
Dumitriu Polysaccharides as biomaterials
JP2012506904A5 (enExample)
JP2015516240A5 (enExample)
Das et al. A polysaccharide-based pH-sensitive hybrid hydrogel as a sustained release matrix for antimicrobial drugs
Wahab et al. Polysaccharides as composite biomaterials
JP2006522829A5 (enExample)
Sirisha et al. Polysaccharide-based nanoparticles as drug delivery systems
Youn et al. Tissue adhesives based on chitosan for biomedical applications
Al-Roujayee et al. Alginate-based systems: advancements in drug delivery and wound healing
Fatima et al. Diversity of rationally modified polysaccharides for pharmaceutical applications
JP2011513393A5 (enExample)
Neamtu et al. Nanogels containing polysaccharides for bioapplications
Abdel-Rahman et al. Hyaluronan/Zinc oxide nanocomposite-based membrane: preparation, characterization, and in vitro and in vivo evaluation